exit targets for current short positions:
AFFX $13
AMGN $52
AGEN $6.75
IDBE $5.75
CTIC $6.75
Input happily accepted on these targets, suggested stops, fresh picks, etc.
Going to throw out OSIP for discussion. Yesterday's news about the DSMB for Tarceva trial recommending against continuation of therapy because of a "safety signal," along with Iressa's safety issues, suggests to me some more downside is possible. No one was impressed with their pipeline of oncology candidates picked up from GILD for $300 million. I haven't looked at financials recently, and may not have time, as I'm headed out this afternoon.
I may be back briefly Sunday night, but expect to be gone for 10 days or so on Monday. Those targets may be considered limit orders; if hit the cover will be made, though the change to the portfolio may not be made until I'm back.
Similarly, if someone wants to pick up the ball on OSIP or something else, and does a good enough job with the DD to impress another biofreak that shorting it is a good idea, I will accept whatever entry they come up with if I'm not around to vet it myself.
Cheers, Tuck |
